Natco Pharma Limited — Financials & Forensics
Sector: Healthcare · NSE: NATCOPHARM · BSE: 524816 · ISIN: INE987B01026
01 Oct 2026
Add NATCOPHARM to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹1,945 Cr | ₹2,707 Cr | ₹3,999 Cr | ₹4,430 Cr | ₹4,078 Cr |
| EBITDA | ₹264 Cr | ₹936 Cr | ₹1,751 Cr | ₹2,196 Cr | ₹1,436 Cr |
| EBITDA margin | 13.6% | 34.6% | 43.8% | 49.6% | 35.2% |
| Profit after tax | ₹170 Cr | ₹715 Cr | ₹1,388 Cr | ₹1,883 Cr | ₹1,418 Cr |
Deeper analysis
Recent filings by Natco Pharma Limited
-
Copy of Newspaper Publication
05 Sep 2026 · Regulatory Compliance
-
Notice of 43rd Annual General Meeting of the Company scheduled to be held on Wednesday, the Septembe
04 Sep 2026 · Corporate Action
-
Business Responsibility and Sustainability Report
04 Sep 2026 · Regulatory Compliance
-
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is schedu
04 Sep 2026 · Board Meeting
-
Analysts/Institutional Investor Meet/Con. Call Updates
02 Sep 2026 · General Update
Never miss a filing again
About Natco Pharma Limited on Indian Stock Alerts
Indian Stock Alerts tracks Natco Pharma Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.